Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer / 부인종양
Journal of Gynecologic Oncology
;
: 311-319, 2015.
Article
in English
| WPRIM
| ID: wpr-123435
ABSTRACT
OBJECTIVE:
There is no research regarding the appropriate antiemetic agents for female patients, especially those receiving moderately emetogenic chemotherapy (MEC). We evaluated the antiemetic efficacy of a combination of 5-HT3 receptor with/without aprepitant in patients with gynecological cancer treated with the TC (paclitaxel and carboplatin) regimen of MEC.METHODS:
We enrolled 38 patients diagnosed with gynecologic cancer and scheduled to receive the TC regimen. The patients were randomly assigned to receive a 5-HT3 receptor antagonist, either palonosetron in the first cycle followed by granisetron in the second cycle or vice versa. In the third cycle, all patients received a combination of the 5-HT3 receptor and dexamethasone with/without aprepitant.RESULTS:
When three drugs were administered, palonosetron consistently produced an equivalent complete response (CR) rate to granisetron in the acute phase (89.5% vs. 86.8%, p=0.87) and delayed phase (60.5% vs. 65.8%, p=0.79). With regard to the change in dietary intake, palonosetron exhibited similar efficacy to granisetron in the acute phase (92.1% vs. 89.4%, p=0.19) and delayed phase (65.7% vs. 68.4%, p=0.14). However, in the delayed phase, the addition of aprepitant therapy with a 5-HT3 receptor antagonist and dexamethasone produced a higher CR rate than a 5-HT3 receptor antagonist with dexamethasone (93.3% vs. 47.8%, p<0.001) and allowed the patients to maintain a higher level of dietary intake (93.3% vs. 56.5%, p<0.001).CONCLUSION:
The addition of aprepitant therapy was more effective than the control therapy of a 5-HT3 receptor antagonist, and dexamethasone in gynecological cancer patients treated with the TC regimen.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Quinuclidines
/
Vomiting
/
Drug Administration Schedule
/
Antineoplastic Combined Chemotherapy Protocols
/
Morpholines
/
Carboplatin
/
Paclitaxel
/
Granisetron
/
Cross-Over Studies
/
Diet
Type of study:
Controlled clinical trial
Limits:
Adult
/
Aged
/
Female
/
Humans
Language:
English
Journal:
Journal of Gynecologic Oncology
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS